Galmed Pharma (GLMD) Tops Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Galmed Pharma (GLMD) Tops Q1 EPS by 12c

Galmed Pharmaceuticals Reports First Quarter 2017 Financial Results

May 15, 2017 8:00 AM EDT

TEL AVIV, Israel, May 15, 2017 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, and other liver diseases, today reported financial results for the three months ended March 31, 2017.  The Company will host a conference call and webcast today to discuss the financial results.

Financial Summary First Quarter 2017 vs. First Quarter 2016:

Net loss of $3.2 million, or $0.26 per share, for the three months ended... More